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Abstract
There is increasing evidence that p63, and specifically DNp63, plays a central role in both development and tumorigenesis
by promoting epithelial cell survival. However, few studies have addressed the molecular mechanisms through which such
important function is exerted. Fatty acid synthase (FASN), a key enzyme that synthesizes long-chain fatty acids and is
involved in both embryogenesis and cancer, has been recently proposed as a direct target of p53 family members, including
p63 and p73. Here we show that knockdown of either total or DN-specific p63 isoforms in squamous cell carcinoma (SCC9)
or immortalized prostate epithelial (iPrEC) cells caused a decrease in cell viability by inducing apoptosis without affecting
the cell cycle. p63 silencing significantly reduced both the expression and the activity of FASN. Importantly, stable
overexpression of either FASN or myristoylated AKT (myr-AKT) was able to partially rescue cells from cell death induced by
p63 silencing. FASN induced AKT phosphorylation and a significant reduction in cell viability was observed when FASN-
overexpressing SCC9 cells were treated with an AKT inhibitor after p63 knockdown, indicating that AKT plays a major role in
FASN-mediated survival. Activated AKT did not cause any alteration in the FASN protein levels but induced its activity,
suggesting that the rescue from apoptosis documented in the p63-silenced cells expressing myr-AKT cells may be partially
mediated by FASN. Finally, we demonstrated that p63 and FASN expression are positively associated in clinical squamous
cell carcinoma samples as well as in the developing prostate. Taken together, our findings demonstrate that FASN is a
functionally relevant target of p63 and is required for mediating its pro-survival effects.
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Introduction
p63 (TP73L/TP63) is a homologue of the p53 tumor suppressor
gene and represents the most ancient member of the p53 family
[1–3]. Because of the presence of two promoters, p63 encodes two
major classes of proteins: those containing a transactivating (TA)
domain homologous to the one present in p53 (i.e. TAp63), and
those that lack the TA domain (i.e. DNp63) [1,2]. In addition,
alternate splicing at the carboxy-terminal (C-terminal) generates at
least three p63 variants (a, b, and c) in each class.
Although p53 and p63 share high sequence and structural
similarities, there are striking differences between their function
and expression profiles. In physiological conditions, the expression
of p63 is mostly restricted to the basal cell compartment of both
stratified and glandular epithelia, with DNp63a being the
predominant isoform [1,4–8]. The analysis of p63-deficient mice
unequivocally demonstrated that p63 plays a very critical role in
the development of epithelial organs/tissues, including the
epidermis and other squamous epithelia, salivary, lachrymal,
mammary, and prostate glands and the bladder urothelium
[4,5,9,10]. Moreover, there is evidence that p63 is essential for the
proliferative potential of stem cells both in the thymus epithelium
and the epidermis [11]. In contrast to p53, p63 is rarely mutated in
human tumors, and its role in cancer appears to be complex and
needs to be further clarified [12–16]. Current data suggest that TA
and DN isoforms might have opposite effects and support a role for
DNp63 in promoting tumorigenesis.
DNp63 is highly expressed in up to 80% of primary head and
neck squamous cell carcinomas (HNSCCs), as well as in
malignancies of other squamous epithelia origin, including lung
and esophageal cancers [15,17–20]. Its overexpression is frequent-
ly associated with the amplification of the genomic locus at 3q27
that harbors the p63 gene [15,17]. In addition, it has been
proposed that aberrant p63 expression may be an early event in
the pathogenesis of HNSCC, as extension of p63 expression is
observed from normal basal cells into suprabasal levels in mucosal
specimens displaying dysplasia [20].
The ectopic expression of DNp63 isoforms has been initially
reported to inhibit p53 transactivation, leading to the early
speculation that overexpression of DNp63 might simply be a
mechanism to inactivate p53 [1,21]. However, p63 inhibition has
been shown to induce apoptosis by upregulating the pro-apoptotic
Bcl-2 family genes Puma and Noxa through a mechanism that is
independent of the p53 status of the cells but requires p73 [22].
Most importantly, subsequent studies have provided evidence that
DNp63 also functions by directly activating the transcription of
specific target genes [23–29]. For instance, it has been shown that
p63 antagonizes apoptosis by regulating cellular adhesion in the
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5877basal cells of the mammary gland and other stratified epithelial
tissues [30]. Nevertheless, the molecular mechanisms mediating
p63 function both during development and tumorigenesis remain
to be fully characterized.
Fatty acid synthase (FASN), a multifunctional enzyme that is
essential for the endogenous synthesis of long-chain fatty acids
from its precursors acetyl-CoA and malonyl-CoA [31], has been
recently shown to be a direct target of DNp63a [32]. Given the
increasing evidence that FASN is critical for cell survival and
might act as a metabolic oncogene, we studied the functional
relevance of FASN regulation by p63. We find that the pro-
survival activity of p63 activity is significantly mediated by FASN
in both transformed and immortalized epithelial cells.
Materials and Methods
Ethics Statement
All research involving human subjects has been conducted on
anonimized, discarded tissues collected from patients during the
course of their therapy. This research has been approved by the DF/
HCC institutional review board. All animal work has been conducted
according to relevant national and international guidelines.
Cell lines and chemicals
The human squamous carcinoma cell line SCC9 was maintained
in DMEM medium (Invitrogen Corporation, Carlsbad, CA)
supplemented with 0.5 mM sodium pyruvate, 1.2 g/L sodium
bicarbonate, 400 ng/ml hydrocortisone, and 10% FBS. SCC9-
Tp63 and SCC9-Dp63 inducible clones, established as described
below, were maintained in DMEM medium supplemented with
0.5 mM sodium pyruvate, 1.2 g/L sodium bicarbonate, 400 ng/ml
hydrocortisone, 10% Tetracycline free FBS (BD Biosciences, San
Jose, CA), 10 mg/ml blasticidin (Sigma-Aldrich, St. Louis, MO), and
300 mg/ml zeocin (Invitrogen Corporation, Carlsbad, CA). Immor-
talized prostate basaloid epithelial cells (iPrEC) (a gift from Dr.
W.C.Hahn, Dana-Farber Cancer Institute, Boston, MA) were
propagated in defined medium (PrEGM) (Lonza, Allendale, NJ), as
recommended [33]. The FAS inhibitor C75 and PI3K inhibitor LY
294002 were purchased from Cayman chemicals, Ann Arbor, MI.
The AKT specific inhibitor InSolution AKT inhibitor VIII, Isozyme-
selective was purchased from EMD chemicals, Inc., Gibbstown, NJ.
siRNA transfection
Tp63 siRNA (CGTATTCCACTGAACTGAA), targeting all
p63 isoforms, Dp63 siRNA (GGACAGCAGCATTGATCAA),
targeting DNp63 isoforms, and Scramble (CAGTCGCGTTTGC-
GACTGG) non-specific siRNA, were purchased from Dharmacon
(Dharmacon Research Inc, Lafayette, CO). One day before
transfection, SCC9 cells were seeded and incubated in DMEM
supplemented with 0.5 mM sodium pyruvate, 1.2 g/L sodium
bicarbonate, 400 ng/ml hydrocortisone and 10% FBS without
antibiotics. The next day, cells at 40% confluency were transfected
with p63 siRNA or Scramble siRNA using oligofectamine
according to the manufacturer’s instructions. For a 100 mm tissue
culture dish, 2 ml of Opti-MEM1 reduced serum medium
containing 40 nmol of siRNA and 40 ml of Oligofectamine
(Invitrogen Corporation, Carlsbad, CA) were added to each plate.
Studies involving smaller plates were scaled down according to the
manufacturer’s recommendations. Cells were harvested and
processed further depending on the type of experiment.
Generation of p63 shRNA inducible cell lines
The pBLOCK-iT inducible RNAi lentiviral expression system
(Invitrogen Corporation, Carlsbad, CA) was used to establish
Tetracycline inducible cells expressing shRNA for p63. First,
SCC9 and iPrEC cells were infected with pLenti6/TR lentiviral
expression construct according to the manufacturer’s protocol.
Stable transfectants were selected by culturing with Blasticidin
(10 mg/ml for SCC9 and 3 mg/ml for iPrEC) (Sigma-Aldrich, St.
Louis, MO). The clones with highest Tet repressor expression
(SCC9 TR, iPrEC TR) were selected for further transfection with
constructs expressing shRNA targeting all or DN-specific p63
isoforms. To this end, Tp63 and Dp63 sequences (see above) were
inserted in pENTER/H1/TO entry vector. pENTER/H1/TO-
Tp63 and pENTER/H1/TO-Dp63 constructs were then recom-
bined with pLenti4/BLOCK-IT DEST Gateway vector to
generate pLenti4/BLOCK-IT-Dp63 and pLenti4/BLOCK-IT-
Tp63 shRNA expression constructs according to manufacturer’s
protocol. SCC9 TR and iPrEC TR clones were incubated with
pLenti4/BLOCK-IT-Dp63 or pLenti4/BLOCK-IT-Tp63 shRNA
viralsupernatantandstabletransfectantswerescreened with Zeocin
(300 mg/ml for SCC9 and 50 mg/ml for iPrEC) (Invitrogen
Corporation, Carlsbad, CA). The selected blasiticidin and zeocin
resistant cells were screened for knockdown of p63 upon addition of
tetracycline (2 mg/ml). Clones with efficient knockdown of p63were
selected and named SCC9-Tp63, SCC9-DP63, iPrEC-Tp63, and
iPrEC-Dp63 depending on cell type and shRNA expression.
Cell viability assay
Cell viability was assessed by using the 3-(4,5-dimethylthiazol-2-
yl)-2,5 diphenyltetrazodium bromide (MTT) assay. MTT (5 mg/
ml) was added to each well to a final concentration of 0.5 mg/ml
and the plates were incubated for 3 h at 37uC. The formazan
product was solubilized with 1 ml of dimethyl sulfoxide (DMSO)
and the absorbance was measured at 590 nm using Perkin Elmer
Victor
3 multilabel counter (Perkin Elmer Life and Analytical
Science, Shelton, CT).
Flow cytometry assays
Cells were incubated with 10 mg/ml of BrdU for 2 h. Adherent
cells were collected using trypsin-EDTA and floating cells were
collected by centrifugation. The cells were combined, washed
twice with PBS, fixed in 70% ethanol, and stored at 220uC. Fixed
cells were permeabilized with 2M HCl, blocked with 0.5% heat
inactivated serum for 1 h, and incubated in BrdU-FITC antibody
(BD Biosciences, San Jose, CA) for 20 min at 4uC. After
incubation, cells were washed with PBS and re-suspended in
300 ml of Propidium Iodide buffer (PBS, 0.1% Triton, 0.05 mg/ml
RNase A, and 10 mg/ml Propidium Iodide) and incubated for
30 min at room temperature. The cells were then analyzed on a
fluorescence-activated cell sorter (FACScan, BD Biosciences, San
Jose, CA) using CellQuest software.
Annexin V staining was performed according to the manufac-
tures protocol (BD Biosciences, San Jose, CA). Briefly, cells were
washed twice with cold PBS and resuspended in 16Binding buffer
at a concentration of 1610
6 cells/ml. To 100 ml of this cells
suspension, 5 ml of Annexin V antibody was added and incubated
for 15 min at room temperature in the dark. After incubation,
400 ml of binding buffer was added to the tube and analyzed on a
fluorescence-activated cell sorter (FACScan, BD Biosciences, San
Jose, CA) using CellQuest software.
Fatty acid synthesis assay
Fatty acid synthesis was measured by incorporation of [2-
14C]
acetate into lipids as described elsewhere [34,35]. Briefly, cells
were plated in 6 well plates at 3X10
5 cells per dish and incubated
overnight. The next day, cells were transfected with siRNAs, as
described above. At several time periods after transfection, cells
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4C] acetate per well for 4 hr.
After incubation, cells were harvested and equal numbers of cells
were suspended in 200 ml of PBS. Lipids were extracted with a 3:1
methanol: chloroform mixture for 30 min with occasional shaking.
After 30 min, an additional 250 ml of methanol and 300 mlo f
water were added. The samples were then centrifuged and the
lower phase was counted for
14C using a Packard 1600CA Tri-
Carb liquid scintillation counter (Packard Instrument Company,
Downers Grove, IL). Each experiment was repeated in triplicates
and the data was expressed as percent of the control.
Western blot analysis
Equal amounts of protein (30 mg) were resolved electrophoret-
ically and transferred to nitrocellulose membranes (Whatman
GmbH, Dassel, Germany). After, blockading with 5% nonfat dry
milk in Tris-buffered saline with 0.1% Tween 20, membranes
were probed with the following primary antibodies: anti-p63
mouse monoclonal antibody (Santa-Cruz Biotechnology, Santa
Cruz, CA), anti-FAS mouse monoclonal antibody (BD Bioscienc-
es, San Jose, CA), anti-phospho AKT rabbit polyclonal antibody
(Cell Signaling Technology, Inc., Danvers, MA), anti-AKT rabbit
polyclonal antibody (Cell Signaling Technology, Inc., Danvers,
MA), anti-phosphoS6 rabbit polyclonal antibody (Cell Signaling
Technology, Inc., Danvers, MA), and anti-cleaved caspase 3,
rabbit monoclonal antibody (Cell Signaling Technology, Inc.,
Danvers, MA). Bound antibody was detected with HRP-
conjugated goat anti-rabbit or goat anti-mouse (Thermo Fisher
Scientific, Rockford, IL) and Immobilon
TM Western chemilumi-
nescent HRP substrate (Millipore Corporation, Temecula, CA).
Real Time PCR studies
Total RNA was extracted using TRIzol reagent (Invitrogen
Corporation, Carlsbad, CA) and cDNA was synthesized by reverse
transcribing 1 mg of total mRNA using reverse transcriptase
(Invitrogen Corporation, Carlsbad, CA), random hexamers (Invi-
trogen Corporation, Carlsbad, CA), and dNTP mixture according
to the manufacturer’s protocol. Real time PCR studies were
performed using SYBR green (Applied Biosystems, Foster City, CA)
on a Bio-Rad MyiQ
TM single color Real-Time PCR detection
system (Bio-Rad Laboratories, Hercules, CA). Eachexperiment was
repeated intriplicatesanddata wasanalyzedusingGene Expression
Macro
TM software (Bio-Rad Laboratories, Hercules, CA).
Squamous cell carcinoma tissue microarrays
De-identified formalin-fixed, paraffin-embedded head and neck
squamous cell carcinoma (HNSCC) tissues were collected from 83
patients who were diagnosed and treated at the Brigham and
Women’s Hospital of Boston, and at the St. James Hospital, Dublin,
Ireland. For each case, three core tissue biopsies (0.6 mm diameter)
were taken from selected representative tumor areas and arrayed in
three new recipient paraffin blocks. For 50% of the cases three
additional tissue cores were taken from morphologically normal-
appearingregions.TumorcharacteristicsaresummarizedinTable1.
Immunohistochemical and statistical analyses
Specimens were immunostained using the following antibodies:
mouse anti-p63 (clone 4A4, dilution 1:200, Santa-Cruz Biotech-
nology, Santa Cruz, CA) and rabbit anti-FASN (dilution 1:200,
Assay Designs, Ann Arbor, MI). Briefly, paraffin embedded tissue
sections were deparaffinized and rehydrated and treated for
antigen retrieval (0.01 M citrate buffer pH 6.0). This step was
followed by incubation with 3% hydrogen peroxide to block
endogenous peroxidase activity. The slides were then incubated
with an optimal dilution of the primary antibodies for 60 minutes
at room temperature. The reaction product was then developed
using DAKO EnVision
TM+ System horseradish peroxidase
detection kit (DAKO North America Inc, Carpinteria, CA) and
counterstained with Hematoxylin. Double immunostaining was
performed as previously described [36]. The double-immuno-
stained slides were scanned using the ScanScopeH slide scanning
system (Aperio Technologies Inc., Vista, CA) and images analyzed
by a Color Deconvolution Algorithm (Aperio Technologies Inc.).
Expression levelsof eachmarker was evaluated bytwo pathologists
(ADN and SS) blinded to clinical and laboratory data. p63 was scored
by estimating the percentage of tumor cells displaying nuclear
staining. Cytoplasmic expression of fatty acid synthase was scored as
negative (no expression), weak expression (1+), moderate expression
(2+), and strong (3+). The mean of all the three cores per tumor was
used as a single value. A cutoff of 65% p63 positive cells was applied
to separate high (.65%) and low (,or equal to 65%) p63 expressors.
A FASN staining intensity $2 was applied to separate high and low
FASN expressors. For frequency analysis in contingency tables,
statistical analysis of associations between variables was performed by
Fisher’s exact test. Statistical significance was set at P#0.05.
Results
Knockdown of either Total or DN specific p63 isoforms
causes a decrease in cell viability
A squamous cell carcinoma cell line (SCC9) and immortalized
prostate basaloid epithelial cells (iPrEC) were utilized to investigate
the molecular pathways that mediate p63 function in epithelial
cells.
Silencing of p63 expression was performed in SCC9 cells
utilizing siRNA oligos, targeting either all p63 isoforms (Tp63
siRNA), or DNp63 isoforms only (Dp63 siRNA). In addition,
tightly regulated p63 silencing was achieved in both SCC9 and
Table 1. Tumor characteristics of the HNSCC cases.
Tumor Characteristics No. (%)
Tumor grade
G1 8 (9.6%)
G2 38 (45.8%)
G3 37 (44.6%)
pT stage
T1 16 (19.3%)
T2 31 (37.3%)
T3 14 (16.9%)
T4 22 (26.5%)
pN stage
NX 8 (9.6%))
NO 35 (42.2%)
N1 11 (13.3%)
N2 26 (31.3%)
N3 3 (3.6%)
pM stage
MX 70 (84.4%)
M0 9 (10.8%)
M1 4 (4.8%)
doi:10.1371/journal.pone.0005877.t001
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short hairpin RNA (shRNA) sequences for either all p63 isoforms
(SCC9-Tp63 and iPrEC-Tp63) or DNp63 isoforms (SCC9-Dp63
and iPrEC-Dp63). Both RNAi methods led to a 60–80% decrease
in p63 protein expression in the targeted cells (Figure 1A–B and
data not shown). As expected, no changes in p63 protein levels
were detected in cells transfected with control siRNA (Scr) or in
clones that were not treated with tetracycline.
Downregulation of p63 expression in both SCC9 and iPrEC
cells resulted in a significant decrease in cell viability. Specifically,
knockdown of p63 in SCC9 cells caused a decrease in the number
of viable cells as early as 48 hours after p63 siRNA transfection as
compared to the scramble control (P=0.02, two-tailed t-test)
(Figure 1C). The effects on cell viability became even more evident
at the later time points. By day 6 (144 h), there was a dramatic
reduction in the viability of cells transfected with either Tp63,
(P=0.006, two-tailed t-test) or Dp63 (P=0.0009, two-tailed t-test)
siRNAs as compared to cells transfected with scramble siRNA.
Similar results were observed upon p63 silencing in the inducible
SCC9 and iPrEC clones (Figure 1D).
Knockdown of either Total or DN specific p63 isoforms
induces apoptosis without affecting the cell cycle
We next assessed whether the decrease in cell viability observed
upon p63 downregulation was a result of apoptosis, cell cycle arrest,
or both. We addressed this question by performing flow cytometric
analysis in both SCC9 and iPrEC cell lines after p63 silencing. We
found that p63 knockdown of either all p63 isoforms or DNp63
isoforms caused a significant increase in the sub G1 population of
cells when compared to the control (P,0.05 at 48, 72, and 96 h,
two-tailed t-test) (Figure 2A–2C, left panels). In line with these data,
knockdown of p63 in both SCC9 and iPrEC cells resulted in an
increase in the cleaved caspase 3 levels and a concomitant decrease
in the expression total caspase 3. Accordingly, cleaved poly (ADP-
ribose) polymerase (PARP) protein levels were increased after p63
knockdown (Figure2D). These data provide evidence that p63plays
a role in the survival of both transformed and immortalized
epithelial cells. The observation that Tp63 and Dp63 siRNAs
produced similar results suggests that p63 anti-apoptotic function is
mostly mediated by DNp63 isoforms.
In contrast to the effects on apoptosis, we did not observe any
noticeable changes in the cell cycle distribution of the p63-silenced
cells compared to their control (Figure 2A–C, right panels). These
results indicate that p63 promotes cell survival without signifi-
cantly affecting cell proliferation.
p63 modulates Fatty Acid Synthase (FASN) levels and
activity
It has recently been suggested that FASN is a conserved target
of p53 family members, including p63 and p73 [32]. Since FASN
has been shown to have anti-apoptotic activity, we investigated
whether the pro-survival function of p63 is mediated by FASN.
As first step, we assessed whether p63 regulates FASN expression
by evaluating the effects p63 downregulation on FASN mRNA and
protein levels. Knockdown of p63, with either Tp63 or Dp63
siRNAs decreased the mRNA expression of FASN by approxi-
mately 50% in the SCC9 cell line (Figure 3A, left and middle
panels). In addition, we observed a similar decrease in FASN
transcript levels after p63 knockdown in iPrEC cells (Figure 3A,
right panel). Consistent with these results, we detected a significant
decrease in FASN protein expression upon knockdown of p63 in
both SCC9 and iPrEC cells (Figure 3B). These data confirm that
p63 modulates FASN expression at both mRNA and protein levels
in both transformed and immortalized epithelial cells.
In order to explore the functional consequences of FASN
downregulation induced by p63 silencing, we investigated fatty
acid synthesis in the p63-silenced cells by assessing C14 acetate
incorporation into cellular lipids. In the SCC9 cell line, p63
knockdown resulted in a significant decrease in fatty acid synthesis
compared to the control (p=0.004, two-tailed t-test). Such
decrease was observed by 48 hr after transfection with siRNAs
and persisted up to the measured time point of 96 h (Figure 3C).
Overlapping results were obtained in SCC9-Tp63 (p=0.009, two-
tailed t-test, 120 h) and iPrEC-Tp63 (p=0.015, two-tailed t-test,
120 h) cells. Taken together, our data demonstrate that p63
silencing causes a significant reduction in both FASN levels and
FASN enzymatic activity.
p63 modulates AKT activation
Phosphatidylinositol-39-kinase (PI-39K)/protein kinase B (AKT)
signaling has been extensively implicated in cell survival and there
is some evidence that AKT might function both upstream and
downstream of FASN [37]. Therefore, we also analyzed the role of
p63 in modulating AKT activation in both transformed and
immortalized epithelial cells. Silencing of p63 in both SCC9 and
iPrEC cells induced a significant decrease in the phosphorylation
of AKT without causing any changes in total AKT levels
(Figure 4). In addition, we observed that p63 silencing resulted
in a decrease in phosphorylation of ribosomal protein S6, which is
a downstream effector of the PI-3K-AKT pathway.
p63 pro-survival function are mediated by FASN and AKT
The observation that p63 regulates both AKT and FASN
activity, suggests that signaling downstream of these molecules
might be required for p63 anti-apoptotic function. We tested this
hypothesis by investigating whether constitutive expression of
FASN or activated-AKT is able to protect cells from the decrease
in cell viability induced by p63 silencing. To this end, SCC9 and
iPrEC cells were stably transfected with FASN, myristoylated
AKT (Myr-AKT) or empty vector (EV). p63 silencing was
achieved in the FASN overexpressing cells (FASN-SCC9 and
FASN-iPrEC), Myr-AKT expressing cells (mAKT-SCC9 and
mAKT-iPrEC) and control cells (EV-SCC9 and EV-iPrEC) by
either transfection of siRNA or by generation of tetracycline-
inducible clones expressing shRNA.
FASN and Myr-AKT overexpressing cells were monitored for
p63 knockdown- induced cell death against cells expressing empty
vector. Forced expression of FASN or activated AKT reduced the
rate of apoptosis observed after p63 downregulation assessed by
both annexin V and PI staining (Figure 5A). In addition, the effects
of FASN and AKT activation on the viability of p63 silenced cells
were assessed by comparing the decrease in number of viable cells
Figure 1. Silencing of either Total or DN specific p63 isoforms causes a decrease in cell viability. A. Immunoblot analysis of p63 in SCC9
cells transfected with Tp63, Dp63 or Scr siRNAs. B. Immunoblot analysis of p63 in tetracycline-inducible clones of SCC9 (SCC9-Tp63, SCC9-Dp63), and
iPrEC (iPrEC-Tp63 and iPrEC-Dp63) with or without treatment with tetracycline. C–D. Cell viability curves. Quantification of cell viability measured by
MTT assay in SCC9 cells transfected with Tp63, Dp63 or Scr siRNAs (C), in SCC9-Tp63 and SCC9-Dp63 cells with or without treatment with tetracycline
(D, upper panel) and in iPrEC-Tp63 and iPrEC-Dp63 cells with or without treatment with tetracycline (D, lower panel). Data are shown as means +/2
standard error and are representative of three independent experiments.
doi:10.1371/journal.pone.0005877.g001
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overexpressing cells versus their respective controls. In accordance
with the apoptosis data, constitutive expression of either FASN or
Myr-AKT significantly, but not completely, rescued the decrease
in cell viability caused by p63 down-regulation (Figure 5B, C).
These results indicate that both FASN and AKT pathways play an
important role in p63-mediated cell survival.
Cross talking between FASN and AKT has been suggested by
various studies. There is some evidence that AKT signaling
induces the expression of FASN and that inhibition of FASN
activity results in downregulation of phospho-AKT [37–40]. In
light of these previous observations, we investigated the cross talk
between FASN and AKT in SCC9 cells.
Overexpression of FASN in SCC9 cells resulted in an increase in
phosphorylation of AKT. Upon knockdown of p63, FASN-SCC9
cells showed a decrease in phospho-AKT expression to levels that
were, however, still significantly higher than those detected in the
EV-SCC9-Tp63 cells (Figure 5D and Figure S1B). These results
Figure 2. Silencing of either Total or DN specific p63 isoforms induces apoptosis with no significant changes in cell proliferation. A–
C. Flow cyometric analysis of SCC9 cells transfected with Tp63, Dp63 or Scr siRNAs (A), SCC9-Tp63 and SCC9-Dp63 cells with or without treatment
tetracycline (B) and iPrEC-Tp63 and iPrEC-Dp63 cells with or without treatment tetracycline (C). Left panels show quantification (percentage) of the
sub G1 population measured by PI staining. Right panels show the fractions of cells in the various phases of the cell cycle, as determined by BrdU
incorporation. Data are shown as means +/2 standard error and are representative of three independent experiments. D. Immunoblot analysis of
apoptosis-related proteins in SCC9 cells transfected with Tp63, Dp63 or Scr siRNAs (left panel), in SCC9-Tp63 cells with or without treatment with
tetracycline (middle panel) and in iPrEC-Tp63 cells with or without treatment with tetracycline (right panel).
doi:10.1371/journal.pone.0005877.g002
Figure 3. p63 silencing induces a decrease in FASN expression and enzymatic activity. A. Quantitation of FASN mRNA by real time RT-PCR
in SCC9 cells transfected with Tp63 or Dp63 siRNA relative to cells transfected with Scr siRNA (left panel). Quantitation of FASN mRNA in SCC9-Tp63
and iPrEC-Tp63 cells treated with tetracycline relative to the correspondent untreated cells (middle and right panels, respectively). Data are shown as
means +/2 standard error and are representative of three independent experiments. B. Immunoblot analysis of FASN in SCC9 cells transfected with
Tp63, Dp63 or Scr siRNAs (left panel), in SCC9-Tp63 cells with or without treatment with tetracycline (middle panel) and in iPrEC-Tp63 cells with or
without treatment with tetracycline (right panel). C. Quantitation of C14 incorporation within cellular lipids in SCC9 cells transfected with Tp63 or
Dp63 siRNA relative to cells transfected with Scr siRNA (left panel) and in SCC9-Tp63 and iPrEC-Tp63 cells treated with tetracycline relative to the
correspondent untreated cells (middle and right panels, respectively). Data are shown as means +/2 standard error and are representative of three
independent experiments.
doi:10.1371/journal.pone.0005877.g003
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PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5877suggest that the resistance to apoptosis conferred by FASN
overexpression in p63-silenced cells could be at least in part due
to activation of AKT signaling. In an attempt to better understand
whether AKT plays a role in this process, we studied the effects of
AKT inhibition in FASN overexpressing cells silenced for p63
expression. We observed a significant reduction in cell viability
when FASN-SCC9 cells were treated with a specific AKT inhibitor
(AKTi, 3 mM) after p63 knockdown (Figure 5E). Thus, AKT
signaling appears to play a role in FASN-mediated survival.
Overexpression of myr-AKT or blockade of PI3K/AKT
pathway (LY and AKT inhibitor) in the same cell line significantly
modulated phospho-AKT levels but did not cause any alteration in
the FASN protein levels, suggesting that AKT does not play a
central role in the regulation of FASN expression in these cells
(Figure S1). Surprisingly, however, FASN activity was significantly
increased by overexpression of myr-AKT and decreased by AKT
inhibition (Figure S2). This result raises the possibility of post-
translational regulation of FASN by AKT and suggests that the
rescue from apoptosis documented in the p63-silenced cells
expressing myr-AKT maybe partially mediated by FASN signaling.
Moreover, this finding indicates that the reduction in viability
caused by AKTi treatment in FASN-SCC9 cells could involve the
inhibition of FASN activity. Of note, the effects of AKTi treatment
on FASN-SCC9 cells appeared to be largely independent of p63
levels (i.e. similar reduction in viability was seen in p63-silenced and
control FASN-SCC9 cells) (Figure 5E). Since ATKi inhibits both
AKT and FASN activities, the observation that p63 levels have
limited impact on the viability of FASN-SCC9 cells treated with
ATKi is consistent with the hypothesis that AKT and FASN are
important mediators of p63 pro-survival function.
p63 and FASN expression are positively associated in
human SCC tissues
Our cell-based assays indicate that FASN is a functionally
relevant target of p63 in SCC cells. If FASN were a main mediator
of p63 function also in human tumors, the levels of the two
proteins would be positively associated in SCC tissues. In order to
test this hypothesis, we examined FASN and p63 protein
expression by immunohistochemistry in a tissue microarray
(TMA) containing cores from 83 cases of head and neck SCC
(HNSCC). The characteristics of the tumors are described in
Table 1. In the morphologically normal epithelium, FASN
expression was weak and restricted to the lower layers. In line
with previous reports, p63 expression was observed in both basal
and parabasal epithelial cell layers (data not shown). Among the 83
tumors, FASN was detected in 95.2% of the cases and p63 in
98.8% of the cases. p63 protein expression was scored by
estimating the percentage of positive nuclei in tumor cells.
Cytoplasmic expression of FASN was scored as negative (no
expression), weak expression (1+), moderate expression (2+), and
strong (3+). Statistical analysis revealed a significant positive
association (p,0.007, Fisher’s exact test) between FASN and p63
expression levels (Table 2). Representative cases are shown in
Figure 6A and Figure S3. Of note, FASN expression was more
intense in the non-keratinizing poorly differentiated tumors with
basaloid morphology, where p63 was found to be positive in
almost 100% of tumor cells (Figure 6A, lower panel). No
significant association was found between tumor grade and FASN
or p63 expression levels (data not shown). These findings are in
line with our in vitro data and further support a role for FASN in
mediating pro-oncogenic p63 functions in vivo.
p63 and FASN co-localize in the urogenital sinus (UGS)
and developing prostate
We have previously shown that p63 is required for the
development of prostate basal cells. The observation that the pro-
survival role of p63 in the prostate basaloid iPrEC cells depends on
FASN, prompted us to investigate a possible association between
p63 and FASN expression in the developing prostate. To this end,
transversal sections of the UGS from a mouse embryo at day E18.5
were double-immunostained for p63 and FASN. Co-localization of
the two proteins was observed in the lower and intermediate layers
of the UGS epithelium as well as in the prostate buds (Figure 6B).
These results suggest that FASN may be an important mediator of
p63 function during prostate development.
Discussion
There is increasing evidence that p63, and specifically DNp63,
plays a critical role in both development and tumorigenesis by
promoting epithelial cell survival [4,10,11,15,27,41]. However,
very few studies have addressed the molecular mechanisms
through which such important function might be exerted. In this
respect, it has been suggested that DNp63 counteracts apoptosis by
repressing the expression of pro-apoptotic genes and by activating
a cell adhesion program [23,24,29,30].
Figure 4. p63 silencing induces a decrease in AKT phosphorylation. Immunoblot analysis of total AKT, phospho-AKT (Ser 473), and phospho-
S6 (Ser 235/236) in SCC9 cells transfected with Tp63, Dp63 or Scr siRNAs (left panel), in SCC9-Tp63 cells with or without treatment with tetracycline
(middle panel) and in iPrEC-Tp63 cells with or without treatment with tetracycline (right panel).
doi:10.1371/journal.pone.0005877.g004
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PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e5877Here we find that p63 is indispensable for the survival of both
iPrEC and SCC9 cells and provide substantial evidence that this
process is mediated by the regulation of lipid metabolism, and
specifically the function of FASN. Our findings show that p63 not
only induces the expression of FASN at both the mRNA and the
protein level but also enhances its enzymatic activity. Most
importantly, stable overexpression of FASN is able to rescue cells
from cell death induced by p63 downregulation.
FASN is a key enzyme that synthesizes long-chain fatty acids
from acetyl-CoA and malonyl-CoA and is essential for embryonic
development. Indeed, FASN knockout mice and most of the
FASN heterozygous mice die in utero [42]. The up-regulation of
FASN expression in numerous types of cancer and its association
with poor outcome have long suggested its role in human
malignancy [43–50]. In line with this hypothesis, inhibition of
the FASN pathway by either FASN inhibitors including C75 or
Cerulenin, or by silencing FASN expression with RNAi result in
G1 arrest and/or induction of apoptosis in various cancers cells
[51–56]. Moreover, recent findings from our group indicate that
FASN functions as a metabolic oncogene in prostate cancer by
inhibiting the intrinsic pathway of apoptosis [57]. Thus, the newly
uncovered regulation of FASN activity by p63 establishes a novel
functional link between this p53 family member and cellular
metabolism. Moreover, it suggests that maintenance of fatty acid
synthesis is one of the mechanisms through which p63 acts as a
pro-survival molecule in both development and cancer.
D’Erchia et al. recently reported that FASN harbors two p53
responsive elements (REs) in its promoter site, and that TAp73a,
and DNp63a, but not p53, TAp73b or TAp63a directly bind to
these elements and modulate expression of FASN at the
transcriptional level [32]. These data indicate that FASN is a
direct target of DNp63 and are in agreement with our observation
that p63 modulates both FASN transcript and protein levels.
Moreover, in our experiments silencing of either total or DNp63
isoforms produced overlapping cell phenotypes, implying that
DNp63 is the major player in controlling cell survival and FASN
activity in epithelial cells.
The finding that p63 silencing decreases phosphorylation of
AKT and of its downstream target S6 suggested that signaling
through the PI3K/AKT pathway is involved in p63 function. This
hypothesis was confirmed by the demonstration that ectopic
expression of myr-AKT conferred protection from apoptosis
induced by p63 loss. Our results are in line with those recently
reported by Ogawa et al. demonstrating that activation of the
AKT pathway is necessary for DNp63a protection against UV
induced apoptosis [58].
A positive feedback loop between FASN and AKT activation
has been proposed [37]. In agreement with previously published
data [39], we observed that FASN sustains AKT activation, raising
the possibility that AKT could function downstream of FASN in
promoting cell survival. In line with this hypothesis, we found that
blocking of the AKT pathway altered FASN-mediated rescue of
cell death in the context of p63 silencing, Thus, AKT appears to
be a critical mediator of FASN signaling, at least in our model
system.
Activated AKT has been shown to increase the expression of
FASN in several types of tumors including ovarian [37] and
prostate cancers [59]. Accordingly, inhibition of the PI3K/AKT
pathway with LY 294002 has been shown to reduce the expression
of FASN [39]. In addition, there is evidence that the transcription
activator SREBP-1c (sterol-regulatory-element-binding protein-
1c), which is a known regulator of FASN expression, is modulated
by both AKT and MAPK pathways [23,37,39,40,60,61].
Surprisingly, we didn’t observe any significant changes in FASN
protein levels either by activating or blocking of the AKT
pathway. Thus, the effects of the AKT pathway in regulating
FASN levels might be cell type specific. In spite of this result, it is
notable that forced expression of myr-AKT did significantly
increase FASN activity, suggesting that additional and perhaps
more general effects of the AKT pathway on post-transcriptional
modification of FASN may be involved.
Overall, the findings that FASN induces AKT phosphorylation
and is activated downstream of AKT highlight the presence of a
positive-feedback loop between FASN and ATK signaling.
Additional experiments are required to unravel the molecular
mechanisms through which AKT signaling modulates FASN
enzymatic activity without affecting its protein levels. It will also be
important to determine whether p63 can induce AKT activation
through mechanisms other than FASN signaling.
Figure 5. Increased FASN or AKT activity protects cells from apoptosis induced by p63 silencing. A. Quantitation of apoptosis by flow
cytometry using Annexin V assay (left panel) or PI staining (right panel) in EV-SCC9, mAKT-SCC9, and FASN-SCC9 cells transfected with either Tp63 or
Scr siRNAs. B. Effects of p63 silencing on the viability of SCC9 and iPrEC cells overexpressing either FASN or empty vector. Upper panels:
Quantification of cell viability in EV-SCC9 and FASN-SCC9 cells transfected with either Tp63 (left panel) or Dp63 (right panel) relative to cells
transfected with Scr siRNA. Lower left panel: Quantification of cell viability in EV-SCC9 and FASN-SCC9 cells carrying inducible Tp63 shRNA (EV-SCC9-
Tp63 and FASN-SCC9-Tp63) treated with tetracycline relative to untreated cells. Lower right panel: Quantification of cell viability in EV-iPrEC and
FASN- iPrEC cells carrying inducible Tp63 shRNA (EV-iPrEC-Tp63 and FASN- iPrEC-Tp63) treated with tetracycline relative to untreated cells. C. Effects
of p63 silencing on the viability of SCC9 and iPrEC cells overexpressing either Myr-AKT or empty vector. Upper panels: Quantification of cell viability in
EV-SCC9 and mAKT-SCC9 cells transfected with either Tp63 (left panel) or Dp63 (right panel) relative to cells transfected with Scr siRNA. Lower left
panel: Quantification of cell viability in EV-SCC9 and mAKT-SCC9 cells carrying inducible Tp63 shRNA (EV-SCC9-Tp63 and FASN-SCC9-Tp63) treated
with tetracycline relative to untreated cells. Lower right panel: Quantification of cell viability in EV-iPrEC and mAKT-iPrEC cells carrying inducible Tp63
shRNA (EV-iPrEC-Tp63 and mAKT-iPrEC-Tp63) treated with tetracycline relative to untreated cells. Data are shown as means +/2 standard error and
are representative of three independent experiments. D. Immunoblot analysis of p63, FASN, phospho-AKT and c-PARP in EV-SCC9-Tp63 and FASN-
SCC9-Tp63 cells with or without treatment with tetracycline. E. Inhibition of AKT signaling significantly affects FASN-mediated rescue of cell death
induced by p63 silencing. The graph shows the viability of EV-SCC9-Tp63 with or without treatment with tetracycline and of FASN-SCC9-Tp63 and
FASN-SCC9-Tp63 cells with or without treatment with an AKT inhibitor and/or tetracycline. Data are shown as means +/2 standard error and are
representative of three independent experiments.
doi:10.1371/journal.pone.0005877.g005
Table 2. Positive association of p63 and FASN expression in
HNSCC cases.
FASN p63 Total
Low (#65%) High (.65%)
Low (,2) 17 (44.74%) 21 (55.26%) 38
High ($2) 7 (15.56%) 38 (84.44%) 45
Total 24 59 83
p,0.007, Fisher’s exact test.
doi:10.1371/journal.pone.0005877.t002
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PLoS ONE | www.plosone.org 11 June 2009 | Volume 4 | Issue 6 | e5877Overexpression of FASN as well as p63 has been previously
demonstrated in squamous cell carcinomas from various organs
[15,18–20,62]. In support of the hypothesis that p63 function is
mediated by FASN, we observed that the expression of FASN and
p63 were positively associated in human HNSCC tissues.
Interestingly, FASN expression levels appeared to be highest in
non-keratinizing poorly differentiated tumors with basaloid
morphology that also expressed very high p63 levels. Moreover,
in a number of well- to moderately-differentiated HNSCCs, p63
and FASN tended to co-localize in the least differentiated cells at
the periphery of the lesion while more differentiated cells in the
central part of the tumor nodules were mostly negative for the
expression of both proteins. While these results are compatible
with current data indicating that FASN is under the control of
multiple oncogenic pathways [17,60,62–65], they seem to support
a model in which p63 sustains FASN expression in the
undifferentiated stem cell-like population of human HNSCC. As
it has recently been suggested that p63 functions in maintaining
the proliferative potential of epidermal stem cells [11], it will be
critical to establish whether the same genetic program plays a role
in cancer stem cells and whether FASN is involved.
FASN is essential for embryonic development and the FASN
gene is broadly expressed in the mouse embryo [42]. By E9.5
FASN expression is evident throughout the epidermis and the
strongest labeling is observed in the distal epidermis of the limb
bud, including the apical ectodermal ridge (AER), a structure that
is critical for limb development and also displays very high p63
levels [4]. The co-localization of FASN and p63 expression in
various embryonic structures, including the UGS epithelium and
developing prostate, supports a role for FASN as a critical
mediator of p63 function during development.
Supporting Information
Figure S1 Inhibition or activation of the AKT pathway does not
alter FAS protein levels. A. SCC9 cells were treated for several
time periods including 24 h, 48 h and 72 h with an AKT inhibitor
(AKTi) and FASN protein expression was analyzed using western
blotting. B. Overexpression of FASN and mAKT in SCC9-Tp63
clones. EV-SCC9-Tp63, mAKT-SCC9-Tp63, and FASN-SCC9-
TP63 cells were treated with tetracycline for 72 h and western
blotting was performed. Overexpression of mAKT didn’t alter
FAS protein levels. However, overexpression of FASN increased
the levels of phospho-AKT.
Found at: doi:10.1371/journal.pone.0005877.s001 (0.46 MB TIF)
Figure S2 Overexpression of myr-AKT or FASN increases
FASN activity. FASN activity was assessed in SCC9, mAKT-
SCC9, and FASN-SCC9 cells treated with an AKT inhibitor,
AKTi (3 mM), or FASN inhibitor, C75 (10 mg/ml) or DMSO
(control) for 4 h using. Both myr-AKT and FASN expression
increased FASN activity compared to their controls. Blocking of
either of these pathways with specific inhibitors decreased the
activity of FASN.
Found at: doi:10.1371/journal.pone.0005877.s002 (0.23 MB TIF)
Figure S3 Co-localization of p63 and FASN in HNSCC whole
tissue section. Whole tissue section of a moderately differentiated
HNSCC double stained for FASN (brown) and p63 (red). There is
a gradient of expression of both p63 and FASN, decreasing from
the periphery to the center of the lesion.
Found at: doi:10.1371/journal.pone.0005877.s003 (5.10 MB TIF)
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